Targeting unmet needs in personalized oncology

XEPTAGEN SpA is engaged in the discovery and validation of novel molecular markers in order to produce innovative diagnostic kits for cancer early detection, monitoring, and evaluation of response to therapy. By exploiting the natural immune response to early stage cancer and the proprietary platform technology Combinatorial Proteomic®, XEPTAGEN has discovered predictive, prognostic and early response tumor markers that lead to an earlier and much more accurate detection of developing carcinomas. Our mission includes creating innovative tools that improve the clinical management of cancer patients.

Latest Product Literature

Biasiolo A, et al. Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study. Dig Liver Dis. 48(2):197-202. 2016.

Cardoso H, et al. Avaliação da acuidade dos níveis séricos de SerpinB3 no diagnóstico de carcinoma hepatocelular. Congresso Português de Hepatologia. Porto, Portugal. 2016.
Biasiolo A, et al. New biomarkers for clinical management of hepatitis C virus infected patients. World J Clin Infect Dis. 5(4):59-66. 2015.

Crescenzi M, et al. Analytical Validation of a Biochip prototype for integrated analysis of AFP-IgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma. Anal Methods. 7:629-637. 2015.

Gallotta A, et al. A novel algorithm based on serum SCCA-IgM determination combined with common clinical data improves prediction of histological NASH. Dig Liver Dis. 47S:e226. 2015.

Liu J, et al. Overexpression of Squamous Cell Carcinoma Antigen 1 Is Associated with the Onset and Progression of Human Hepatocellular Carcinoma. Arch. Med. Res. S0188-4409. 2015.